Start-ups are our most efficient means of transforming innovations into products, but the process of converting a scientific advance into a valuable company is opaque and haphazard. This talk will present a systematic framework for successful innovation. We will explore how to: navigate the academic/entrepreneurial interface; define, perceive, and convey value at all stages of an idea or company; and ideate, experiment, and persuade with purpose. <br/><br/>Dr. Mata-Fink is a biotechnology leader, entrepreneur, author, and inventor. Based for many years at Flagship Pioneering in Cambridge, MA, his work has led to the creation of multiple valuable public and private biotechnology companies including: CYGNAL THERAPEUTICS, developing drugs that target neuronal pathways for the treatment of cancer and inflammation; RUBIUS THERAPEUTICS (NASDAQ: RUBY), developing engineered red blood cells as a safe, potent, and long-lasting cellular therapy; and EDITAS MEDICINE (NASDAQ: EDIT), developing the first CRISPR/Cas9-based genome editing therapies for human disease.

Field guide to scientific entrepreneurship

Macromolecular Chemistry: The Second Century

[Author Benefits](https://scimeetings.acs.org/?utm_source=pubs_content_marketing&utm_medium=website&utm_campaign=0320_MCF_NPI_Launch_Spring_Homepage&ref=pubs_content_marketing)

[How to use SciMeetings](https://storage.googleapis.com/dl.morressier.com/acs/SciMeetings-ACSSpring2020-HowToGuide_M3020-Final.pdf)

[Frequently Asked Questions](https://storage.googleapis.com/dl.morressier.com/acs/SciMtng_ACSNMSp2020_FAQ_M3120_Final.pdf)

ACS Spring 2020 National Meeting & Expo

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.